Recipharm Completes Korean Serialization Project for Abbott
News Mar 19, 2015
Recipharm has announced further serialization success with the completion of a complex serialization project for Korea for one of its leading customers; Abbott. The initiative, which commenced in April 2014, is now completed.
The CDMO met the precise customer and market requirement to produce a data matrix code, including serial number, with full compliance with complex regulations, similar to foreseen EU rules.
Recipharm applied its internationally adaptable solution, designed to achieve full compliance with country specific regulations, to a blister packaging line; with the need differing markedly from Chinese serialization. Validation batches are now manufactured released and planned to be shipped to Korea mid-March 2015.
Recipharm applied its successful methodology to the project initiated for the top ten pharmaceutical customer. From the outset, integration formed a key tenet with the establishment of joint company strategic teams and the sharing of critical information. Costs were kept to a minimum and full implementation achieved.
Stephane Guisado, General Manager at Recipharm in Fontaine commented: “We are delighted with the success of this serialization project for the Korean market carried out for Abbott, a long standing pharma partner of ours. Once again, our serialization platform solution has proved the extent of its adaptability and resourcefulness for differing geographic and multi-country regulatory requirements. Indeed, in this case, it ensured that our customer complied in full with the relevant serialization regulations set down by Korea”, He continued: “We were pleased to have received such strong thanks and recognition from the Abbott project team for the work that we staged on this project. We look forward to rolling out further projects during 2015.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE